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Edited by Angel NebredaAbstract Chemotherapeutic agents are well known to induce
growth arrest of cancerous cells by inducing DNA damage/repli-
cational stress and engaging cellular apoptotic machinery. Our
studies on hydroxyurea (HU) recognized cyclin D1 destabiliza-
tion as the initiator of growth arrest at G1/S-phase independent
of other cell cycle regulators. Cyclin D1 degradation was associ-
ated with its phosphorylation at Thr286 by glycogen synthase
kinase-3b and inactivation of Akt kinase. Overexpression of
the cyclin D1T286A mutant, or constitutively active Akt, con-
ferred stability to cyclin D1 and helped bypass cell cycle arrest.
Thus, growth arrest by HU seems to involve destabilization of
cyclin D1 in addition to its well-established role as ribonucleotide
reductase inhibitor.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The DNA damaging agents appear to be a powerful tool
under therapeutic setting not only for preventing active prolif-
eration of cancerous cells but also engaging the apoptotic
machinery through p53-dependent activation of their tran-
scriptional targets [1,2]. The replicational stresses normally in-
volve activation of ATR (ataxia telangiectasia mutated and
Rad3-related) kinase that in turn activates multiple substrates
such as p53, BRCA1 and Chk1 required for DNA repair and
cell cycle checkpoint regulation [3,4]. Growth arrest at G1/S-
phase by ionizing radiation is known to be mediated by p53-
dependent transactivation of p21Waf1 gene and inhibition in
the catalytic activity of the cyclin E–cdk2 complex [5]. The
ATR-dependent cell cycle arrest in S and G2/M phases, on
the other hand, is mediated by Chk1-dependent phosphoryla-Abbreviations: ATR, ataxia telangiectasia mutated and Rad3-related
kinase; CA, constitutively active; FACS, ﬂuorescence activated cell
sorting; GSK-3b, glycogen synthase kinase-3b; GST, glutathione
S-transferase; HA, hemagglutinin; HU, hydroxyurea; IP, immunopre-
cipitation; PI, pre-immune serum treated; Rb, retinoblastoma; RT-
PCR, reverse transcriptase-dependent polymerase chain reaction; WB,
Western blotting
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doi:10.1016/j.febslet.2008.02.068tion and consequent inhibition of cdc25 family of phospha-
tases resulting in down regulation of cdk1/cdk2 activities
[6,7]. The decreased cdk2 activity enforces growth arrest at
G1/S-phase when cells undergo DNA replication and centro-
some duplication. Further, defects in DNA damage signaling
lead to failure in the DNA repair process, genetic instability,
chromosomal aberrations and ultimately carcinogenesis [8].
Therefore, a thorough understanding of cellular response to
replicational stress is crucial for the prevention and treatment
of cancer [9].
Agents like hydroxyurea (HU) are well known to induce
genotoxic stress by stalling replicational fork and causing dou-
ble-stranded DNA breaks that eventually leads to growth ar-
rest or apoptotic cell death [10]. HU – a potent inhibitor of
ribonucleotide reductase – has been widely used in clinics to
treat a range of diseases including chronic myelogenous leuke-
mia and hemoglobinopathies [11,12] and synchronizing yeast
and mammalian cells in culture [13,14]. While the inability of
cells to enforce growth arrest may lead to apoptotic death,
the molecular mechanism(s) by which cells respond to HU
treatment is not fully understood. In this study, we have eluci-
dated new molecular events that seem to assist growth arrest
by HU at G1/S-phase.2. Materials and methods
2.1. DNA constructs, recombinant proteins and peptides
Details of various expression vectors can be found elsewhere:
FLAG-T286A-cyclin D1 [15]; GSK-3b-KD [16]; hemagglutinin
(HA)-tagged constitutively active (CA) Akt (HA–CA–Akt) [17]. Cyclin
D1T286A-EGFP vector was made by cloning FLAG-T286A-cyclin D1
into the pIRES2-EGFP plasmid (Clontech, USA).
siRNA against GSK-3b, GSK-3b peptide substrate and recombi-
nant glutathione S-transferase (GST)-retinoblastoma (Rb) were from
Cell Signaling Technology Inc. (Massachusetts, USA); Histone H1
was from Roche (Germany); recombinant GST-p53 was from Santa
Cruz Biotechnology (California, USA).
2.2. Chemicals, radio-chemicals and antibodies
The chemical inhibitors used and their working concentrations were:
Cycloheximide (Chx; 10 lg/ml) and hydroxyurea (HU; 2–400 mM) (all
Sigma–Aldrich). MG132 (20 lg/ml) and 1-Azakenpaullone (Akp,
10 lM) were from Calbiochem. Cells were treated for 90 min with
inhibitors prior to lysate preparation. MG132 and Akp were present
during the labeling as well as chase periods following HU treatment.
All radio-chemicals were obtained from New England Nuclear (Mas-
sachusetts, USA).
Antibodies for cyclin D1-T286, p38, pP38-T180/Y182, phospho-Rb-
S807/811 and phospho-Akt-S473 were from Cell Signaling Technology
Inc. Anti-FLAG antibody was from Sigma–Aldrich. All other anti-
bodies were from Santa Cruz Biotechnology.blished by Elsevier B.V. All rights reserved.
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Huh7, HEK293 and NIH3T3 cells (5 · 105 cells/60 mm dish) were
synchronized by serum starvation for 72 h which led to majority of
cells (>65%) in G0/G1-phase [18]. The G1-synchronized cells were ser-
um-stimulated (4–6 h) prior to HU-treatment and subsequent studies.
Cells were transfected with diﬀerent recombinant plasmids (3 lg) using
Lipofectin [18]. Pulse-chase was done in synchronized cells by labeling
with [35S]-cysteine-methione mix (200 lCi for 30 min) followed by a
wash with two volumes of fresh medium supplemented with 10% fetal
bovine serum. Fluorescence activated cell sorting (FACS) analysis of
cells was performed as described previously [18].2.4. Other biochemical methods
Total RNA isolation and semi-quantitative reverse transcriptase-
dependent polymerase chain reaction (RT-PCR) for cyclin E,
p21Waf1 and b-actin was performed as described previously [18]. The
oligonucleotide primers for p21Waf1 were: p21 (F) 5 0-GCGATG-
GAACTTCGACTTTGT-3 0 and p21 (R) 5 0-GGGCTTCCTCTTG-
GAGAAGAT-3 0. The PCR products of 446, 586 and 352 bp were
obtained, respectively, for b-actin, cyclin E and p21waf1.
Methods for immunoprecipitation (IM), Western blotting (WB) and
in vitro phosphorylation assays have been described earlier [18].3. Results
3.1. Growth arrest by hydroxyurea involves destabilization of
cyclin D1
To understand the molecular mechanism of genotoxic stress
induced by HU and to determine a concentration well toler-
ated by cells in culture, HEK293 and NIH3T3 cells were trea-
ted with 2, 20 or 200 mM of HU and analyzed by ﬂow
cytometry. Both cell lines showed a signiﬁcant G1/S blockade
at all concentrations of HU (Table 1). The overall distribution
of cells in the cell cycle including dead cell population was
comparable across the HU concentration used (Supplementary
Fig. 1). To understand the molecular mechanism of HU-in-
duced growth arrest, the levels of key regulators of G1/S-phase
were measured. We observed a rapid destabilization of cyclin
D1 – the main cyclin driving G1 to S progression [19] – at low-
est (2 mM) to highest concentrations (400 mM) of HU
(Fig. 1A). Untreated cells showed no change in the levels of cy-
clin D1 (Fig. 1A). No change in the levels of cdc25A – a medi-
ator of cell cycle arrest following ionizing radiation [20] – was
observed either (Fig. 1B). Interestingly, a gradual accumula-
tion of p21Waf1 was observed post-HU treatment (Fig. 1C).
Analysis of p21Waf1 transcripts also showed a progressive in-
crease in its levels (Supplementary Fig. 2A). The stability of
cdk4 and other regulators like p16Ink, p19Arf and cdc6 wasTable 1
Flow cytometric analysis HEK293 and NIH3T3 cells treated with hydroxyu
Groups % Distribution of cells during cell cyclea means
HEK293
G0/G1 S G2/M
1. Control (asyn.) 54.9 ± 0.2 28.4 ± 0.4 14.1 ±
2. HU (2 mM) 68.0 ± 1.1a 21.2 ± 0.9a 9.3 ±
3. HU (20 mM) 63.5 ± 0.4a 21.4 ± 0.5a 12.2 ±
4. HU (200 mM) 66.4 ± 0.3a 21.3 ± 0.3a 10.8 ±
Cells were cultured in the presence of indicated concentrations of hydroxyur
ﬂow cytometry.
Level of signiﬁcance: a, P < 0.001 and b, P < 0.01 between the corresponding
4.
aAnalysis using Watson pragmatic algorithm; S.E.M., standard error of meanot aﬀected (Fig. 1D). Though the levels of p27Kip1 did not
change signiﬁcantly during the course of experiment (data
not shown), there was a considerable decrease in its phosphor-
ylation by cyclin E-associated kinase activity (Fig. 1E). Like-
wise, a reduction in the Rb phosphorylation was also observed
in the presence of HU (Fig. 1F). Since the HU-mediated desta-
bilization of cyclin D1 was observed in these p53 positive cells
without any sign of cytotoxicity at as high as 200 mM of HU
(Supplementary Fig. 3), the subsequent studies were carried
out at this concentration of HU.
3.2. Hydroxyurea-induced cyclin D1 destabilization is a
post-translational event
To establish whether cyclin D1 destabilization under the HU
stress was a translational or a post-translational event, western
blot analysis of cyclin D1 was carried out in the presence of
cycloheximide. A progressive decrease in cyclin D1 levels in
the HU-treated cells as compared to control cells ruled out
the possibility of a decreased protein synthesis in the presence
of HU (Fig. 2A). Further, its improved stability in the presence
of MG-132 (Fig. 2B) and a rise in phosphorylation at threo-
nine-286 on HU-treatment (Fig. 2C) implicated the proteaso-
mal machinery in cyclin D1 destabilization [15].3.3. GSK-3b mediates cyclin D1 destabilization under HU stress
The intracellular levels of cyclin D1 is known to be regulated
by its phosphorylation at Thr286 by glycogen synthase kinase
3b (GSK-3b) followed by its ubiquitin-dependent proteasomal
degradation [21]. Since an increase in cyclin D1 phosphoryla-
tion was observed on HU-treatment, the role played by
GSK-3b in the process was investigated. As shown in
Fig. 3A, pretreatment with azakenpaullone – a GSK-3b inhib-
itor [22] conferred stability to cyclin D1 under these condi-
tions. Further, regulation of GSK-3b levels by siRNA or
co-expression of GSK-3b-KD also conferred stability to cyclin
D1 in the presence of HU (Fig. 3B and C). Interestingly, over-
expression of the cyclin D1T286A mutant also blocked the
HU-induced degradation of cyclin D1 (Fig. 3C). Under these
conditions, the phosphorylation status of Rb remained largely
uncompromised compared to the mock cells (Fig. 3D). Fur-
ther, cyclin D1T286A overexpression helped in overcoming the
HU-induced G1/S arrest of cell cycle (data not shown). Since
cyclin D1 is a substrate of GSK-3b, the possibility of interac-
tion between the two molecules was investigated. Our co-
immunoprecipitation studies (Fig. 3E) suggested a sustained
interaction between cyclin D1 and GSK-3b.rea
± S.E.M. (n = 3)
NIH3T3
G0/G1 S G2/M
0.5 61.3 ± 0.8 19.1 ± 0.4 16.5 ± 0.3
0.2a 73.8 ± 1.4a 13.9 ± 0.2a 11.8 ± 0.9a
0.2b 75.7 ± 0.12a 11.2 ± 1.1a 13.0 ± 0.7a
0.2a 76.4 ± 0.7a 13.0 ± 0.3a 11.4 ± 0.6a
ea (HU) for 24 h and after staining with propidium iodide analyzed by
phases of cell cycle of control group 1 and HU-treated groups 2, 3 and
n; asyn., asynchrounous.
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Fig. 1. Mediators of growth arrest induced by hydroxyurea (HU). Serum synchronized Huh7 cells were treated with indicated concentrations of HU
up to 90 min (A) or with 0.2 M HU (B–F) for indicated time periods and the cell extracts were used for measuring the levels of diﬀerent cell cycle
regulators. (A) Western blotting (WB) of cyclin D1 and total Rb. (B) Immunoprecipitation (IP) of cdc25A. WB analysis of p21Waf1 and b-actin (C) or
p16Ink, p19Arf, cdk4 and cdc6 (D). (E) In vitro phosphorylation (IVP) of p27Kip1 by cyclin E immunoprecipitate. The endogenous p27Kip1 from
untreated cells were immunopuriﬁed and used as substrate for the cyclin E immunoprecipitate from the HU-treated cells as described earlier [18]. The
same membrane was re-probed for p27Kip1 and cyclin E levels. (F) WB analysis of total and phosphorylated Rb. PI, pre-immune serum.
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activation
HU is reported to stall the replication fork which requires
active participation of ATR homologue in yeast [18,33]. Since
our experiments suggested the involvement of both general sig-
naling cascade as well as checkpoint kinases, the activation/
inhibition kinetics of diﬀerent signaling kinases was monitored
within a window of 5–90 min after HU treatment. This time
frame was chosen considering rapid signaling response leading
to cyclin D1 degradation. Fig. 4 shows that there was a rapid
activation of ATR dependent checkpoint kinase Chk1 with in-
creased phosphorylation at serine-345 residue. The same tem-
poral window showed an inhibition in the levels of active PKB/
Akt kinase (Serine-473 dephosphorylation). Further, we ob-
served a kinetically delayed activation of p38MAPK and a
transient inhibition of serine-9 phosphorylation of GSK3b –
an immediate target of Akt – which later returned to basal
level. The ERK pathway, however, remained unaﬀected under
these conditions.
3.5. Constitutive PKB/Akt activity overrides HU induced
G1/S-phase arrest
As our results showed inhibition of Akt kinase and delayed
phosphorylation of p53 at serine-15 under HU stress (Supple-
mentary Fig. 2B), we investigated whether a constitutive Aktactivity would be suﬃcient to extend a proliferative advantage
to cells in the presence of HU. Cyclin D1 stability and the
phosphorylation status of Rb were analyzed following ectopic
expression of a CA mutant of Akt (HA–CA–Akt) [17]. As
shown in Fig. 5A, expression of CA–Akt not only provided
requisite stability to cyclin D1 but also maintained the hyper-
phosphorylation of pRb. Further, in vitro phosphorylation
studies using cyclin E and Akt immunocomplexes suggested
the maintenance of associated kinase activities (Fig. 5B and
C). Interestingly, the ATR kinase activity was maintained in
the presence of HU (Fig. 5C).4. Discussion
One of the basic outcomes of the activation of checkpoint ki-
nases following exposure to myriads of potentially genotoxic
or DNA damaging agents is to enforce growth arrest. This
provides cells a window for genome repair activities or leads
to apoptotic death. Therefore, understanding the details of
such innate defense mechanisms may be crucial for our war
against cancer. In the present study, we have revisited the
molecular mechanisms of growth arrest by HU in mammalian
cells and provide evidence for the involvement of cyclin D1 in
the process.
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without or with GSK-3b inhibitor 1-azakenpaullone (Akp) followed by immunoprecipitation (IP) for cyclin D1. The densitometric data of cyclin D1
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leukemia and other myeloproliferative disorders for over 30
years [11,12]. It is considered to trigger an apoptotic responseby stalling replication forks and promoting double-stranded
breaks [23,24]. A p53-dependent reversible arrest at G0/G1-
phase has also been reported via ribonucleotide depletion with-
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with HU (0.2 M) and harvested at indicated times points.
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low (2 mM) and high concentrations (200 mM) of HU elicited
a similar G1/S arrest without causing apoptotic cell death. Our
investigations on the biochemical basis of growth arrest iden-
tiﬁed destabilization of cyclin D1 as the initiating event. Other
key regulators like p16Ink, p19Arf, cdk4, cdc6 and cdc25A [6,26]A
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parallel set of transfections were immunoprecipitated (IP) either with ant
associated kinase activity in vitro using appropriate substrates. PI, pre-immuwere stable. Although, a delayed accumulation of p21Cip1 was
observed in our experiments, it is unlikely to mediate such
rapid HU stress signaling as reported earlier for UV-induced
stress [27]. Interestingly, no change in the levels of p27Kip1
was observed which seems to be due to decreased kinase activ-
ity of the cyclin E–cdk2 complex. Further, the Rb phosphory-
lation also declined which may relate to the deregulated cdk2
activity under HU stress. Thus, HU appears to enforce growth
arrest not only by inhibiting its well known target ribonucleo-
tide reductase but also by using cell cycle regulators like cyclin
D1.
Phosphorylation at Thr286 and proteasomal degradation of
cyclin D1 is considered as a prerequisite for normal progres-
sion of the S-phase [15,28]. The HU-induced cyclin D1 desta-
bilization was dependent on its phosphorylation at Thr286 by
GSK-3b since the overexpression of cyclin D1T286A mutant not
only stabilized cyclin D1 and phosphorylated Rb but also
helped in overcoming growth arrest. This was accompanied
by transient activation of GSK-3b through dephosphorylation
of Serine-9. Although, GSK-3b activity returned to normal in
the presence of continued Akt inactivation involving other ki-
nases such as S6K1 [29]. Thus, GSK-3b appears to be an arbi-
ter of cell fate towards proliferation, arrest or apoptosis.
Further, it would also be interesting to investigate the role of
P38 in stress signaling already known to induce c-Fos phos-
phorylation and gene trans-activation following UV stress
[30] and to characterize the molecules that facilitate cross-talk
between checkpoint kinases and mitogenic signaling under
genotoxic stress. In fact a recent report suggests that ATR
can transiently activate GSK-3b following UV irradiation
[31]. Thus, besides a down-regulated Akt activity, a high basalα-Cyclin E (WB)
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instability of cyclin D1.
Another noteworthy observation was on the delayed phos-
phorylation of p53 at serine-15 residue, which is a hallmark
of its transcriptional competence following DNA damage
[32]. This was further corroborated by a delayed induction of
its well known transcriptional target p21Waf1 when compared
to the initiation of cyclin D1 degradation [33]. Thus, the pres-
ent work establishes cyclin D1 degradation as a causal factor
for p53-independent growth arrest at G1/S-phase.
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